Today marks a defining moment in the history of Ocumetics—and in the future of vision restoration worldwide.
It is with great pride and anticipation that I share we are now entering the final stages before our First-In-Human (FIH) clinical study for the Ocumetics Lens. This is more than a corporate milestone; it is the beginning of a new chapter in medical innovation. For the first time, our revolutionary accommodating intraocular lens is preparing to be implanted in human subjects.
This is historic.
Years of tireless research, engineering, and regulatory preparation have brought us to this pivotal point. Our team has worked diligently to ensure that every element of the development process has met the highest standards of safety, efficacy, and precision. From the successful demonstration of accommodative power to the production of optimized, design-locked lenses, each step has validated the immense potential of the Ocumetics Lens.
We remain on track to begin surgeries this summer. This is not just the culmination of our efforts—it is the true beginning of what we set out to accomplish. Following the procedures, we will begin a 12-month post-operative monitoring period and prepare for the next critical phase: submitting to the FDA for pivotal clinical trials, anticipated to begin in 2026.
This achievement belongs to all of us—our team, our partners, and especially you, our shareholders. Your continued belief in our mission has made this milestone possible.
As we stand on the threshold of transforming how cataracts are treated and how natural vision is restored, I want to personally thank you for your support.
We are not just witnessing history. We are making it.
Best regards,
Dean Burns
President, CEO, and Director
Ocumetics Technology Corp.
Key Highlights Group Two clinical study underway – Patient recruitment has begun in Mexico City, with surgeries targeted for Fall 2026. Moving beyond safety – The Group Two study will evaluate the Ocumetics Lens for safety plus near-and distance-vision performance. Next-generation technology – Patients will receive the latest-generation Ocumetics Lens implanted with an enhanced delivery system. 12-month data milestone approaching – Group One patients are
Calgary, Alberta – TheNewswire – August 24, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the third and final tranche of the private placement previously announced by the Corporation on July 7, July 29, July 30, 2026 and July 31, 2026 (the “Offering”). The Corporation
Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses Production and testing of next-generation lenses now underway New lens design incorporates insights from Group One First-in-Human study Group Two preclinical surgeries targeted for early Q3 2026 FDA Investigational Device Exemption (IDE) preparation advancing Calgary, Canada – TheNewswire – May 12, 2026
Calgary, Alberta – TheNewswire – April 29, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to
